RxDoctor Payments Data

Pamela Morong

Psychiatric/Mental Health · Johnson City, TNNPI 1043828965

Payments from drug & device makers

$1,734in general payments, 2019–2025

Across 88 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$527
  • AbbVie$487
  • Neurocrine Biosciences, Inc.$208
  • Axsome Therapeutics, Inc.$136
  • Otsuka America Pharmaceutical, Inc.$122
  • Gilead$94
  • plus $160 from 4 others

What the payments were for

  • Food & beverage$1,734100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,734 in reported general payments places this provider in the 65th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$11,816
Medicare patients
11
Services billed
90

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl53$75,911
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl548$21,689
RexultiBrexpiprazole11$17,375
SuboxoneBuprenorphine Hcl/Naloxone Hcl21$5,557
Clonazepam271$1,980
Naloxone Hcl24$1,384
Hydroxyzine Hcl32$900
Quetiapine Fumarate56$801
Duloxetine Hcl34$661
Venlafaxine Hcl ErVenlafaxine Hcl29$578
Desvenlafaxine Succinate ErDesvenlafaxine Succinate13$470
Diazepam46$313
Bupropion Hcl40$282
Gabapentin40$261
Olanzapine18$252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$487$75,91153 claims
Otsuka America Pharmaceutical, Inc.Rexulti$122$17,37511 claims
Indivior Inc.Suboxone$54$5,55721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Johnson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →